Galena nets $11.6mn from common stock offering to support NeuVax studies
This article was originally published in Scrip
Executive Summary
Galena Biopharma, a US firm focused on oncology, will net $11.6 million to advance its cancer immunotherapy NeuVax from the sale of 8.5 million shares of common stock at $1.50 per share in an offering set to close on 11 April.